



Billing Code 4410-09-M

DEPARTMENT OF JUSTICE  
DRUG ENFORCEMENT ADMINISTRATION  
IMPORTER OF CONTROLLED SUBSTANCES  
NOTICE OF APPLICATION  
AKORN, INC.

Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this is notice that on May 31, 2012, Akorn, Inc., 1222 W. Grand Avenue, Decatur, Illinois 62522, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of Remifentanil (9739), a basic class of controlled substance listed in schedule II.

The company plans to import Remifentanil in bulk for use in dosage-form manufacturing.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedules I or II, which fall under the authority of section 1002(a)(2)(B) of the Act [21 USC § 952(a)(2)(B)] may, in the circumstances set forth in 21 USC § 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a

hearing on such application pursuant to 21 CFR § 1301.43 and in such form as prescribed by 21 CFR § 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than [INSERT DATE 30 DAYS FROM DATE OF PUBLICATION].

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745-46, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required

to demonstrate to the Deputy Assistant Administrator,  
Office of Diversion Control, Drug Enforcement  
Administration, that the requirements for such registration  
pursuant to 21 USC § 958(a); 21 USC § 823(a); and 21 CFR §  
1301.34(b), (c), (d), (e), and (f) are satisfied.

Joseph T. Rannazzisi  
Deputy Assistant Administrator  
Office of Diversion Control  
Drug Enforcement Administration

DATED: July 17, 2012